Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 831

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 831
---
, amounting to USD $300 thousand, will be repaid to the Company plus annual interest at a rate of 9% for the outstanding period, in 3 equal installments, the last of which was to be transferred to the Company no later than July 31, 2024 and to which the interest accrued during the period would be added. The balance of the loan was recorded in accounts receivable. As of June 30, 2024, the balance of the loan was USD $188 thousand and financing income was recorded in respect thereof amounting to USD $8 thousand. As of the date of these financial statements, the Company has collected all payments in accordance with the separation agreement, and as of December 31, 2024, there is no balance outstanding. H.Agreement with Pluri Inc. On July 17, 2024, the Company entered into a collaboration agreement with Pluri Inc. (Nasdaq: PLUR) (hereinafter, “Pluri”) for the clinical manufacturing (outsourced) of the Company’s products (hereinafter, the “Pluri Agreement”) at Pluri’s manufacturing facility in accordance with the Company’s strategic plan. The signing of the Pluri Agreement to manufacture the Company’s products constitutes a milestone in the development of the ASTRORX ®product, as part of the Company’s preparation for a multi -sitePhase IIA clinical trial (Phase A2), as well as in the development of the ISLETRX product in support of the Pre -INDsubmission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment within the framework of the aforementioned collaboration and as preparation for the submission of an IND application in the future. In accordance with the agreement, the Company will grant Pluri the right to use the knowledge developed by the Company for the benefit of Pluri’s production of the Company’s products, with the first phase lasting up to 12 months, in consideration of approximately USD $70,000 to be paid in cash or through issuance of Company securities, as to be agreed upon by the parties. I.On November 5, 2024, following approval by the Company’s Board of Directors, the Company entered into a definitive and binding merger agreement with the Swiss biopharmaceutical company NLS, whose shares are traded in the United States on the Nasdaq Stock Exchange under the symbol “NLSP”, which develops innovative treatments for rare and complex disorders of the central nervous system, and which was approved by the